Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer
Condition(s):Renal Cancer; Birt-Hogg-Dube SyndromeLast Updated:March 22, 2019Terminated
Hide Studies Not Open or Pending
Condition(s):Renal Cancer; Birt-Hogg-Dube SyndromeLast Updated:March 22, 2019Terminated
Condition(s):Renal Cancer MetastaticLast Updated:March 15, 2022Unknown status
Condition(s):Contrast Enhanced UltrasoundLast Updated:November 12, 2020Unknown status
Condition(s):Benign Kidney Neoplasm; Kidney Neoplasm; Renal Cell CancerLast Updated:October 12, 2023Recruiting
Condition(s):Kidney NeoplasmsLast Updated:November 13, 2023Active, not recruiting
Condition(s):Kidney CancerLast Updated:July 2, 2019Not yet recruiting
Condition(s):Kidney CancerLast Updated:November 8, 2023Recruiting
Condition(s):Kidney NeoplasmsLast Updated:May 28, 2010Terminated
Condition(s):Kidney NeoplasmsLast Updated:April 26, 2017Unknown status
Condition(s):Childhood Kidney Neoplasm; Clear Cell Renal Cell Carcinoma; Congenital Mesoblastic Nephroma; Rhabdoid Tumor of the KidneyLast Updated:August 7, 2018Withdrawn
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.